Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients.

Trial Profile

Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Levofloxacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Therapeutic Use
  • Sponsors Mpex Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results of pooled prespecified analysis of MPEX204,MPEX207 and MPEX209 studies presented at the 113th International Conference of the American Thoracic Society.
    • 14 Sep 2009 Top-line results have been reported in a MPEX Pharmaceuticals media release.
    • 14 Sep 2009 Primary endpoint 'bacteriological response' and 'bacteriological colonisation' has been met according to a MPEX Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top